Experimental stem cell shot aims to stop transplant rejection in blood cancer patients

NCT ID NCT04328714

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This early-stage study tested whether giving patients a special type of stem cell (called interferon gamma-primed mesenchymal stromal cells) around the time of a bone marrow transplant could safely prevent graft-versus-host disease, a serious complication where donor cells attack the patient's body. The study included 4 adults and children with blood cancers or myelodysplastic syndrome. The main goals were to see if the stem cells could be prepared successfully and if they caused any severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Healthcare of Atlanta at Egleston

    Atlanta, Georgia, 30322, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.